This document has been prepared to help provide you with information about our Optiphi DNA Cancer Tests. It is important that you read this information carefully and completely.
Optiphi Helix Breast, Ovarian and Prostrate Cancer Risk Test
The intention of the Helix Breast, Ovarian and Prostrate Cancer Test is to screen a ® optiphi panel of markers that have been commonly associated with the development of breast cancer with some markers also associated with increased risk for ovarian and prostate cancer. The screening of these markers creates awareness to the potential risks associated with these cancers.
There are over 1000 mutations in BRCA1 and BRCA2, but not all of them are high risk and most are classified as harmless. Therefore, has selected a smaller panel of markers in ® Optiphi the BRCA1, BRCA2, ATM, CHEK2, TP53, NBN and PALB2 genes which together contribute to an increased genetic risk.
From this panel of markers, it is possible to determine an odds ratio based on the detected mutations. This odds ratio is not a diagnostic value, but merely a guide to determine the risk ratio from a genetic perspective, it is not intended to be a diagnosis or prediction for future health.
It is important to understand that there are several risk factors involved in breast cancer, with genetics contributing only a portion to overall susceptibility.